Global cancer statistics, CA Cancer J Clin, vol.61, pp.69-90, 2011. ,
Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, vol.359, pp.378-90, 2008. ,
Pivotal role of mTOR signaling in hepatocellular carcinoma, Gastroenterology, vol.135, pp.1-11, 2008. ,
Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends, J Hepatol, vol.60, pp.855-65, 2014. ,
Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma, Oncol Rep, vol.31, pp.573-80, 2014. ,
mTOR signaling in growth control and disease, Cell, vol.149, pp.274-93, 2012. ,
Design and reporting of targeted anti-cancer preclinical studies: a metaanalysis of animal studies investigating sorafenib antitumor efficacy, Cancer Res, vol.76, pp.4627-4663, 2016. ,
an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis, Hepatology, vol.41, pp.307-321, 2005. ,
-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin -2-amine (ARQ 092): an orally bioavailable, selective, and potent allosteric AKT inhibitor, J Med Chem, vol.3, issue.3, pp.6455-69, 2016. ,
Hepatocellular carcinoma cell lines from diethylnitrosamine phenobarbital-treated rats. Characterization and sensitivity to endothall, a protein serine/threonine phosphatase-2A inhibitor, Hepatology, vol.29, pp.1406-1423, 1999. ,
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma, Hepatology, vol.59, pp.1577-90, 2014. ,
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma, J Hepatol, vol.57, pp.592-601, 2012. ,
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3, World J Gastroenterol, vol.17, pp.3922-3954, 2011. ,
Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study, Br J Radiol, vol.87, 2014. ,
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase, Liver Transpl, vol.19, pp.507-527, 2013. ,
Development of PI3K inhibitors: lessons learned from early clinical trials, Nat Rev Clin Oncol, vol.10, pp.143-53, 2013. ,
, Mol Cancer Ther, vol.16, pp.2157-2165, 2017.
,